Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease

Brain Research

Volumn 1200, Issue , 2008, Pages 159-168

  Wilson, Barnabas ^a   Samanta, Malay Kumar ^a   Santhi, Kumaraswamy ^b   Kumar, Kokilampal Perumal Sampath ^a   Paramakrishnan, Nallupillai ^a   Suresh, Bhojraj ^a  

^a JSS COLLEGE OF PHARMACY   (India)

^b AIMST UNIVERSITY   (Malaysia)

Author keywords

Blood brain barrier; Brain targeting; Nanoparticles; Poly(n butylcyanoacrylate); Rivastigmine

Indexed keywords

CYANOACRYLATE DERIVATIVE; NANOPARTICLE; POLY(N BUTYLCRANOACRYLATE); POLYMER; POLYSORBATE 80; RIVASTIGMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BINDING; DRUG BRAIN LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG UPTAKE; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; ZETA POTENTIAL;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; ENBUCRILATE; MALE; NANOPARTICLES; PHENYLCARBAMATES; POLYSORBATES; RATS; RATS, WISTAR; SURFACE-ACTIVE AGENTS; UP-REGULATION;

EID: 40849097322     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.01.039     Document Type: Article

References (75)

1. Agnihotri S.A., Mallikarjuna N.N., and Aminabhavi T.M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Control. Release 100 (2004) 5-28
2. Allemann E., Gurny R., and Deolker E. Drug loaded nanoparticles: preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39 (1993) 173-191
3. Alyautdin R.N., Gothier D., Petrov V.E., Kharkevich D.A., and Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 41 (1995) 44-48
4. Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., and Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Pharm. Res. 14 (1997) 325-328
5. Alyautdin R.N., Tezikov E.B., Ramge P., Kharkevich D.A., Begley D.J., and Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles: an in situ brain perfusion study. J. Microencapsul 15 (1998) 67-74
6. Anonymous. Alzheimer's Association (2003). http://www.alz.org/AD/statistics.htm (Accessed November 11, 2003 from http://www.alz.org/AD/statistics.htm)
7. Banerjee T., Mitra S., Singh A.K., Sharma R.K., and Maitra A. Preparation and biodistribution of ultrafine chitosan nanoparticles. Int. J. Pharm. 243 (2002) 93-105
8. Bayomi M.A., Al-Suwaych S.A., El-Helw A.M., and Mesnad A.F. Preparation of casein chitosan microspheres containing diltiazem hydrochloride by an aqueous coacervation technique. Pharm. Acta Helv. 73 (1998) 187-192
9. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104 (2004) 29-45
10. Behan N., Birkinshaw C., and Clarke N. Poly(n-butylcyanoacrylate) nanoparticles: a mechanistic study of polymerization and particle formation. Biomaterials 22 (2001) 1335-1344
11. Bodor N., and Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev. 36 (1999) 229-254
12. Bodor N., Prokai L., Wu W.M., Farag H.H., Jonnalagadda S., Kawamura M., and Simpkins J. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 257 (1992) 1698-1700
13. Borchard G., Audus K.L., Shi F., and Kreuter J. Uptake of surfactant-coated poly(methylmethacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int. J. Pharm. 110 (1994) 29-35
14. Brightman M.W. Morphology of blood-brain barrier. Exp. Eye Res. 25 (1977) 1-25
15. Brookmeyer R., Gray S., and Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88 (1998) 1337-1342
16. Chiannilkulchai N., Ammoury N., Caillou B., Devissageut J., and Couvreur P. Hepatic tissue distribution of doxorubicin loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastases-bearing mice. Cancer Chemother. Pharmacol. 26 (1990) 122-126
17. Cirrito J.R., and Holtzman D.H. Amyloid β and Alzheimer's disease therapeutics: the devil may be in details. J. Clin. Invest. 112 (2003) 321-323
18. Costa P., and Lobo J.M.S. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13 (2001) 123-133
19. Couvreur P., Kante B., Roland M., Guiot P., Baudini P., and Speiser P. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 31 (1979) 331-332
20. Couvreur, P., Roland, M., Speiser, P., 1985. Procedé de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques ques les contenant. European Patent No. 0064967.
21. Cummings J.L. Alzheimer's disease. N. Engl. J. Med. 351 (2004) 56-57
22. Devineni D., Klein-Szanto A., and Gallo J.M. Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. J. Neuro-oncol. 24 (1995) 143-152
23. Douglas S.J., Illum L., Davis S.S., and Kreuter J. Particle size and size distribution of poly(butyl-2-cyanoacrylate) nanoparticles. J. Colloid Interface Sci. 101 (1984) 49-158
24. Ehrlich P. Collected Papers of Paul Ehrlich: Immunology and Cancer Research (1902), Pergamon Press, London 442
25. Evans D.A. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 68 (1990) 267-289
26. Fahmy T.M., Fong P.M., Goyal A., and Saltzman W.M. Targeted for drug delivery. Nanotoday August 18-26 (2005)
27. Fawaz F., Guyot M., Lagueny A.M., and Devissaguet J.Ph. Ciprofloxacin-loaded poly(isobutylcyanoacrylate) nanoparticles: preparation and characterization. Int. J. Pharm. 154 (1997) 191-203
28. Friese A., Seiller E., Quack G., Lorenz B., and Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 49 (2000) 103-109
29. Gao S., Hendrie H.C., Hall K.S., and Hui S. The relationship between age, sex, and the incidence of dementia and Alzheimer's disease: a meta-analysis. Arch. Gen. Psychiatry 55 (1998) 809-815
30. Gavini E., Hegge A.B., Rassu G., Sanna V., Testa C., Pirisino G., Karlsen J., and Giunchedi P. Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int. J. Pharm. 307 (2005) 9-15
31. Genta I., Costantini M., Asti A., Conti B., and Montanari L. Influence of glutaraldehyde on drug release and mucoadhesive properties of chitosan microspheres. Carbohydr. Polym. 36 (1998) 81-88
32. Green J.D., Baddelay A.D., and Hodges J.R. Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia 34 (1996) 537-551
33. Grislain L., Couvreur P., Lenaerts M., Roland M., Deprez-decampeneere D., and Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 15 (1983) 335-345
34. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Ya., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 (1999) 1564-1569
35. Hans M.L., and Lowman A.M. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 6 (2002) 319-327
36. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. Alzheimer's disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60 (2003) 1119-1122
37. Hejazi R., and Amiji M. Stomach-specific anti-H. pylori therapy part III: effect of chitosan microspheres crosslinking on the gastric residence and local tetracycline concentrations in fasted gerbils. Int. J. Pharm. 272 (2004) 99-108
38. Huwyler J., Wu D., and Pardridge W.M. Brain delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14164-14169
39. Janzer R.C., and Raff M.C. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325 (1987) 253-257
40. Kirk A., and Kertesz A. On drawing impairment in Alzheimer's disease. Arch. Neurol. 48 (1991) 73-77
41. Kreuter J. Nanoparticle systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 (2001) 65-81
42. Kreuter J., Alyautdin R.N., Kharkevich D.A., and Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674 (1995) 171-174
43. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., and Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 10 (2002) 317-325
44. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., Alyautdin R.N., von Briesen H., and Begley D.J. Direct evidence that Polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanism requiring prior binding of drugs to the nanoparticles. Pharm. Res. 20 (2003) 409-416
45. Lazartigues E., Freslon J.-L., Tellioglu T., Brefel-Courbon C., Pelat M., Tran M.-A., Montastruc J.-L., and Rascol O. Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat. Eur. J. Pharmacol. 361 (1998) 61-71
46. Lenaerts V., Nagerlkerke J.F., Van Berkel T.J.C., Couvreur P., Grislain L., Roland M., and Speiser P. In vivo uptake of poly(isobutylcyanoacrylate) nanoparticles by the rat liver Kupffer, endothelial and parenchymal cells. J. Pharm. Sci. 73 (1984) 980-982
47. Löbenberg R., Araujo L., von Brisen H., Rodgers E., and Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Control. Release 50 (1998) 21-30
48. Marchal-Heussler L., Maincent P., Hoffman M., Spittler J., and Couvreur P. Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutyl cyanoacrylate nanoparticles preparations. Int. J. Pharm. 58 (1990) 115-122
49. Muller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47 (2001) 3-19
50. Neuwelt E.A., and Dahlborg S.A. Blood-brain barrier disruption in the treatment of brain tumors: Clinical implications. In: Neuwelt E.A. (Ed). Implications of the Blood Brain Barrier and its Manipulation: Clinical Aspects vol. 2 (1989), Plennum Press, New York 195-262
51. Nordberg A., and Svensson A.L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Safety 19 (1998) 465-480
52. Pardridge W.M., Buciak J.L., and Friden P.M. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 259 (1991) 66-70
53. Price B.H., Gurvit H., Weintraub S., Geula C., Leimkuhler E., and Mesulam M. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease. Arch. Neurol. 50 (1993) 931-937
54. Ramge P., Kreuter J., and Lemmer B. Circadian phase-dependent antinociceptive reaction in mice after i.v. injection of dalargin-loaded nanoparticles determined by the hot-plate test and the tail-flick test. Chronobiol. Int. 17 (1999) 767-777
55. Reddy L.H., and Murthy R.S.R. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butylcyanoacrylate) nanoparticles synthesized by two different techniques. Biomed. Pap. 148 (2004) 161-166
56. Roesler M., Klein H.E., and Ackenheil M. An open study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia. Presentation at ACNP, Puerto Rico, December (2002)
57. Schroeder U., and Sabel B.A. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res. 710 (1996) 121-124
58. Schroeder U., Sommerfeld P., Ulrich S., and Sabel B.A. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 87 (1998) 1305-1307
59. 3H-labelled dalargin bound to poly(butylcyanoacrylate) nanoparticles after i.v. injections to mice. Life Sci. 66 (2000) 495-502
60. Seijo B., Fattal E., Roblot-Treupel L., and Couvreur P. Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading. Int. J. Pharm. 62 (1990) 1-7
61. Selkoe D.J. The origins of Alzheimer's disease: A is for amyloid. JAMA 283 (2000) 1615-1617
62. Smith Q.R. Quantitation of blood-brain barrier permeability. In: Neuwelt E.A. (Ed). Implications of the Blood-Brain Barrier and its Manipulation (1989), Plenum, New York 85-113
63. Spillantini M.G., and Goedert M. The protein pathology in neurodegenerative diseases. Trends Neurosci. 21 (1998) 428-433
64. Standaert D.G., and Young A.B. Treatment of central nervous system. Degenerative disorders. In: Hardman J.G., and Limbard L.E. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics (2001), Mc Graw-Hill, New York 560
65. Stewart P.A., and Tuor U.I. Blood-eye barriers in the rat: correlation of ultrastructure with function. J. Comp. Neurol. 340 (1994) 566-576
66. Tamai I., and Tsuji A. Drug delivery through the blood brain barrier. Adv. Drug Deliv. Rev. 19 (1996) 401-424
67. Tröster S.D., Müller U., and Kreuter J. Modification of the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61 (1990) 85-100
68. Verdun C., Couvreur P., Vranckx H., Lenaerts V., and Roland M. Development of a nanoparticles controlled-release formulation for human use. J. Control. Release 3 (1986) 205-210
69. Vila A., Sánchez A., Tobío M., Calvo P., and Alonso M.J. Design of biodegradable particles for protein delivery. J. Control. Release 78 (2002) 15-24
70. Vorbrodt A.W. Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J. Neurocytol. 18 (1989) 359-368
71. Williams B.R., Nazarians A., and Gill M.A. A review of rivastigmine: a reversible cholinesterase inhibitor. Clin. Ther. 25 (2003) 1634-1653
72. Wimo A., and Winblad B. Health economical aspects of Alzheimer's disease and its treatment. Psychogeriatrics 1 (2001) 189-193
73. Wisse E., and Leeuw A.M. Structural elements determining transport and exchange process in the liver. In: Daviss S.S., Illum L., McVie J.G., and Tomlinson E. (Eds). Microspheres and Drug Therapy, Pharmaceutical, Immunological and Medical Aspects (1984), Elsevier, Amsterdam 1-23
74. Wu Y., Yang W., Wang C., Hu J., and Fu S. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int. J. Pharm. 295 (2005) 235-245
75. Zhang Z., Liao G., Nagai T., and Hou S. Mitoxantrone polybutyl cyanoacrylate nanoparticles as an anti-neoplastic targeting drug delivery system. Int. J. Pharm. 139 (1996) 1-8